Anebulo Pharmaceuticals, Inc.

ANEB Healthcare Biotechnology

In the quarter to December 2025, EPS grew 44.4% and free cash flow grew 6.58%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.

0.00 0.31 −100.00%
Market cap
$17.6M
P/E
0.0×
Fwd P/E
—
Dividend yield
—
F-score
n/a
Altman Z
n/a
Beneish M
n/a
Dividend safety
n/a
Dec '25 Sep '25 Jun '25 Mar '25 Older periods
Current Ratio
6.24 10.93 24.53 25.29

+8 more quarters

Net Debt/EBITDA
3.47 4.62 5.03 8.06
Debt/Equity
0.00 0.00 0.00 0.00
Free Cash Flow per Share
(0.03) (0.03) (0.05) (0.04)
Book value per Share
0.19 0.24 0.34 0.33
Free Cash Flow
(1.31) (1.27) (1.65) (1.60)
Other line items

Show all line items

Columns are period end dates